VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: 68.8 million
Fully diluted: 83.7 million
--------------------------------------
A detailed introduction commentary to VentriPoint Diagnostics, a unique medical imaging technology company can be accessed by clicking here.
Along with our detailed commentary, please note that VentriPoint made an important announcement today (Nov. 29) regarding a strategic placement of its technology in a prestigious research Hospital in Oslo, Norway.
The news announcement about installing a VMS system in the ‘Riks’ hospital in Oslo is quite extraordinary for VentriPoint on several levels. Firstly, according to VentriPoint management, this is one of the world’s pre-eminent research hospitals.Obviously the VMS system appears to answer a need they are researching and it must have passed a fairly high standard of rigor to be accepted in this prestigious institution. Secondly, the VMS tool must offer something unique as this hospital has every modern diagnostic tool that the major HealthCare providers have developed in the western world.
Note: “The ease of use of the system and its potential to replace MRI studies will hopefully make a difference in the care of children with congenital heart disease," said Dr. Henrik Brun, cardiologist at Rikshospitalet. This is encouraging at this stage in the company’s commercialization as it needs endorsement from leading medical facilities.
On another level, the peer review of the VMS system will be heightened by the fact that the GE HealthCare houses all their leading technology at ‘Riks’ and will probably be watching how the system performs; not a bad thing for future potential relationship development.
VentriPoint’s plan is to strategically place its product in institutions, which will increase the company’s profile, and expand its product offering. Each institution chosen will be running a research trial on a specific congenital heart disease. This will produce a study from a leading cardiologist and information that will be used by the company to create a database for product development. We expect this to enhance the company’s position and move the commercialization process along as quickly as possible.
Click here for information on 'Riks'
VentriPoint’s plan is to strategically place its product in institutions, which will increase the company’s profile, and expand its product offering. Each institution chosen will be running a research trial on a specific congenital heart disease. This will produce a study from a leading cardiologist and information that will be used by the company to create a database for product development. We expect this to enhance the company’s position and move the commercialization process along as quickly as possible.
Click here for information on 'Riks'
0 comments:
Post a Comment